$2.01
1.52% (Daily)
Market Cap
$219.39M
Revenue
$69.05M
Rank by MCap
#1793
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Arnon Rosenthal Ph.D.
Headquarters
South San Francisco, CA
Employees
156
Alector, Inc., a late-stage clinical biotechnology company, develops therapies that is focused on counteracting the devastating progression of neurodegenerative diseases. The company's products under development include Latozinemab (AL001), an investigational human recombinant monoclonal antibody designed to elevate progranulin (PGRN), a protein encoded by the granulin (GRN) gene that regulates lysosomal function, neuronal survival, and inflammation in the brain. Its lead PGRN-elevating candi...
Loading chart…